Introducing a breakthrough known as 'CT1812'

Ocrevus (ocrelizumab) was approved in the US by the FDA in March 2017 for the treatment of adults with relapsing or primary progressive forms of MS, based on three clinical trials.

As we await the arrival of edaravone to US pharmacies, patients can access edaravone now through TheSocialMedwork.

What are the results from the clinical studies that led to the approval of edaravone, and how can patients access it in their country?

For the first time in 22 years, the US Food and Drug Administration (FDA) has approved a drug to treat patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease; a motor neuron disease characterised by muscular atrophy and weakness.

Promising Results from Multiple Studies

The FDA approval of a promising new drug is offering new hope to multiple myeloma patients who have already been through various treatments. 

A new treatment that targets a specific type of lung cancer has received FDA approval. 

The Pharmaceutical and Medical Device Agency (PMDA), has granted marketing approval for the use of Edaravone for the treatment of ALS in Japan.